Scientific Reports (Feb 2024)

Exploring the impact of stage and tumor site on colorectal cancer survival: Bayesian survival modeling

  • Shayesteh Alinia,
  • Samira Ahmadi,
  • Zahra Mohammadi,
  • Farzaneh Rastkar Shirvandeh,
  • Mohammad Asghari-Jafarabadi,
  • Leila Mahmoudi,
  • Malihe Safari,
  • Ghodratollah Roshanaei

DOI
https://doi.org/10.1038/s41598-024-54943-8
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Colorectal cancer is a prevalent malignancy with global significance. This retrospective study aimed to investigate the influence of stage and tumor site on survival outcomes in 284 colorectal cancer patients diagnosed between 2001 and 2017. Patients were categorized into four groups based on tumor site (colon and rectum) and disease stage (early stage and advanced stage). Demographic characteristics, treatment modalities, and survival outcomes were recorded. Bayesian survival modeling was performed using semi-competing risks illness-death models with an accelerated failure time (AFT) approach, utilizing R 4.1 software. Results demonstrated significantly higher time ratios for disease recurrence (TR = 1.712, 95% CI 1.489–2.197), mortality without recurrence (TR = 1.933, 1.480–2.510), and mortality after recurrence (TR = 1.847, 1.147–2.178) in early-stage colon cancer compared to early-stage rectal cancer. Furthermore, patients with advanced-stage rectal cancer exhibited shorter survival times for disease recurrence than patients with early-stage colon cancer. The interaction effect between the disease site and cancer stage was not significant. These findings, derived from the optimal Bayesian log-normal model for terminal and non-terminal events, highlight the importance of early detection and effective management strategies for colon cancer. Early-stage colon cancer demonstrated improved survival rates for disease recurrence, mortality without recurrence, and mortality after recurrence compared to other stages. Early intervention and comprehensive care are crucial to enhance prognosis and minimize adverse events in colon cancer patients.

Keywords